721 filings
8-K
APTO
Aptose Biosciences Inc
1 May 24
Entry into a Material Definitive Agreement
4:30pm
PRE 14A
APTO
Aptose Biosciences Inc
Preliminary proxy
30 Apr 24
5:21pm
10-K/A
2023 FY
APTO
Aptose Biosciences Inc
Annual report (amended)
29 Apr 24
5:19pm
8-K
APTO
Aptose Biosciences Inc
26 Apr 24
Entry into a Material Definitive Agreement
7:30am
8-K
APTO
Aptose Biosciences Inc
5 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:05pm
8-K
0xpf3 01v
26 Mar 24
Aptose Reports Results for the Fourth Quarter and Full Year 2023
4:04pm
8-K
ejcjvcqkt2yh9az bvd
18 Mar 24
Regulation FD Disclosure
4:45pm
8-K
7g6aya
1 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
b7mam6my ptnm5gd
31 Jan 24
Regulation FD Disclosure
4:02pm
8-K
0gpzr
29 Jan 24
Entry into a Material Definitive Agreement
9:44pm
424B4
d7ix35v 8cdba4tkckaz
26 Jan 24
Prospectus supplement with pricing info
5:30pm
8-K
rb1e2ac84ry9
26 Jan 24
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
8:00am
EFFECT
nkix277
26 Jan 24
Notice of effectiveness
12:15am
S-1MEF
80qt7a0p
25 Jan 24
Registration of additional securities for an S-1
9:44pm
CORRESP
cgksyw
24 Jan 24
Correspondence with SEC
12:00am
CORRESP
da8332468o ag
24 Jan 24
Correspondence with SEC
12:00am
8-K
jxtl7lk vx5abmwh
11 Dec 23
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
6:30am